Drugs

Apr 8, 2024, 16:01

Rahul Gosain: Trastuzumab Deruxtecan now is FDA approved, Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02

Rahul Gosain, Co-Founder of Oncology Brothers podcast and Director of Regional Infusion Services and Medical Director at Wilmot Cancer Institute, recently shared on LinkedIn:

“Trastuzumab Deruxtecan now FDA approved for pan-tumor with HER2 IHC3 and solid tumors who have received prior systemic treatment and have no alternative treatment options.

Based on DESTINY-PanTumor02, DESTINY-Lung01, and DESTINY-CRC02:

Dose 5.4 mg/kg
Common AE: fatigue, decreased counts and nausea. ILD can be fatal.”

Source: Rahul Gosain/LinkedIn

cancer DESTINY-CRC02 DESTINY-Lung01 DESTINY-PanTumor02 fatigue FDA HER2 IHC3 nausea OncoDaily Oncology pan-tumor Rahul Gosain solid tumors TDxd Trastuzumab deruxtecan

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage